查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933380

子宮內膜異位症治療市場規模、佔有率、成長及全球產業分析：依類型、應用、區域洞察及預測（2026-2034 年）

Endometriosis Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

子宮內膜異位症治療市場成長驅動因子

全球子宮內膜異位症治療市場持續穩定成長，主要受疾病認知度提高、診斷率上升以及育齡女性對先進治療方案需求成長的推動。子宮內膜異位症是一種慢性婦科疾病，會促使骨盆腔疼痛、不孕症和生活品質下降，因此需要長期有效的治療方法。根據 Fortune Business Insights 預測，全球子宮內膜異位症治療市場規模預計將在 2025 年達到 23.9 億美元，這反映了該治療領域日益增長的臨床和商業重要性。

市場規模及預測

預計到2026年，市場規模將成長至25.8億美元，主要得益於診斷基礎設施的改善、專科護理的普及以及創新藥物療法的推出。在預測期內，市場預計將顯著擴張，到2034年達到50.3億美元，複合年增長率（CAGR）為8.70%。

預計到2025年，北美將主導全球市場，佔49.60%的市場佔有率，這主要歸功於該地區較高的疾病認知度、完善的醫保報銷體係以及眾多大型製藥公司的存在。

市場驅動因素

子宮內膜異位症治療市場的主要驅動因素是對創新和疾病改善型治療方案日益增長的需求。 傳統療法嚴重依賴荷爾蒙抑制，這通常會促使骨密度下降、情緒波動和不孕症等副作用。這些限制促使人們迫切需要更安全、非荷爾蒙標靶療法，以解決發炎、免疫功能障礙和病灶生長等問題。

製藥公司正積極投資研發，以滿足這些未被滿足的需求。例如，2025年1月，Celmatix Therapeutics啟動了一項針對子宮內膜異位症疼痛和發炎的新型JNK抑制劑的開發項目，凸顯了該行業向創新轉型的趨勢。

市場限制因子

儘管市場呈現成長趨勢，但高昂的治療費用仍是一個主要限制因素。口服GnRH拮抗劑等先進療法的價格遠高於一般荷爾蒙療法，這限制了保險覆蓋不足的患者獲得治療的機會。高額的自付費用往往會促使患者依從性差，最終促使治療中斷。

例如，據報道，Orilissa 的標價為每劑 1,046.66 美元，凸顯了患者和醫療保健系統面臨的經濟負擔。

市場機會

研發投入的增加為市場帶來了豐厚的成長機會。由於目前一線療法的療效有限，藥廠正致力於開發安全性更高、療效更持久的新型療法。

2025 年 1 月，Gesynta Pharma AB 獲得了 2,870 萬美元的 B 輪融資，用於推進其子宮內膜異位症候選藥物 vipoglanstat 的 II 期臨床試驗。這些投資有望加速其產品線的開發和未來的市場擴張。

市場趨勢

值得關注的市場趨勢包括擴大宣傳活動和病患權益倡議工作。 這些努力有助於促進早期診斷，減少對經痛的歧視，並教育病人和醫護人員。

例如，2025年3月，國際婦產科超音波學會（ISUOG）舉辦了“2025年子宮內膜異位症宣傳月”，旨在提高全球診斷率並促進治療普及。

市場挑戰

專利侵權和法律糾紛對市場成長構成重大挑戰。專利相關的訴訟會縮短創新藥的獨佔期，使仿製藥能提前進入市場，進而侵蝕收入。

2025年5月，艾伯維公司（AbbVie Inc.）就其產品Orilissa對Hetero Labs Ltd.提起專利侵權訴訟，凸顯了該領域創新公司面臨的法律風險。

市場區隔分析

依藥物類型劃分， "其他" 細分市場佔主導地位，這主要得益於傳統且經濟有效的治療方法的廣泛應用。 Orilissa 預計在 2026 年將佔 11.18% 的市場佔有率，而 Myfembree/Ryeqo 則有望因近期獲準而實現較高的複合年增長率。

依藥物類別劃分，GnRH 拮抗劑在 2025 年佔市場主導地位，預計在 2026 年將佔 40.17% 的市場佔有率。這主要歸功於其起效迅速和安全性更高。

依給藥途徑劃分，口服給藥途徑將在 2026 年佔領先地位，市場佔有率將達到 65.46%，這主要得益於患者依從性高和給藥便利性。

依分銷管道劃分，藥房和零售藥房將引領市場，到 2026 年將佔 59.20% 的市場佔有率。

區域展望

北美預計將引領市場，在 2025 年達到 11.9 億美元，2026 年達到 12.8 億美元，這主要得益於其完善的醫療保健基礎設施和疾病盛行率的上升。

預計到 2025 年，歐洲市場規模將達到 5.6 億美元，而亞太地區，在中印兩國日益增長的認知度推動下，預計到 2025 年將達到 4.6 億美元。

預計拉丁美洲和中東及非洲市場將呈現溫和成長，到 2025 年，市場規模分別為 9,000 萬美元和 5,000 萬美元。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵資訊洞察

  • 主要國家的監管環境
  • 主要公司產品線分析
  • 主要國家的子宮內膜異位症流行病學
  • 主要產業趨勢（併購、合作、新產品發表等）

第五章：全球子宮內膜異位症治療市場分析、洞察與預測（2021-2034）

  • 依治療藥物劃分的市場分析、洞察與預測
    • Orilissa
    • Myfembree/Lyco
    • 其他
  • 依治療類別劃分的市場分析、洞察與預測
    • GnRH拮抗劑
    • GnRH激動劑
    • 其他
  • 市場分析、洞察與預測 - 依給藥途徑
    • 口服
    • 其他
  • 市場分析、洞察與預測 - 依銷售管道
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美子宮內膜異位症治療市場分析、洞察與預測，2021-2034

  • 依國家/地區
    • 美國各州
    • 加拿大

第七章：歐洲子宮內膜異位症治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區子宮內膜異位症治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳大利亞
    • 亞太其他地區

第九章：拉丁美洲子宮內膜異位症治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東與非洲子宮內膜異位症治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2026）
  • 公司簡介
  • Gesynta Pharma AB
  • Gesynta Pharma AB
  • AbbVie Inc.
  • Pfizer Inc.
  • Organon group of companies.
  • Bayer AG
  • AstraZeneca
  • Sumitomo Pharma Co., Ltd.
Product Code: FBI114330

Growth Factors of endometriosis treatment Market

The global endometriosis treatment market is witnessing steady expansion, driven by increasing disease awareness, rising diagnosis rates, and growing demand for advanced therapeutic solutions among women of reproductive age. Endometriosis is a chronic gynecological condition associated with pelvic pain, infertility, and reduced quality of life, creating a significant need for long-term and effective treatment options. According to Fortune Business Insights, the global endometriosis treatment market was valued at USD 2.39 billion in 2025, reflecting the growing clinical and commercial importance of this therapeutic area.

Market Size and Forecast

In 2026, the market is projected to grow to USD 2.58 billion, supported by improved diagnostic infrastructure, increasing access to specialty care, and the introduction of innovative drug therapies. Over the forecast period, the market is expected to expand significantly and reach USD 5.03 billion by 2034, registering a CAGR of 8.70%.

North America dominated the global market in 2025, accounting for a 49.60% market share, owing to high disease awareness, strong reimbursement frameworks, and the presence of leading pharmaceutical companies.

Market Drivers

A major driver of the endometriosis treatment market is the increasing demand for innovative and disease-modifying treatment alternatives. Traditional therapies rely heavily on hormonal suppression, which often results in adverse effects such as bone density loss, mood changes, and fertility concerns. These limitations have created strong demand for safer, non-hormonal, and targeted therapies that address inflammation, immune dysfunction, and lesion growth.

Pharmaceutical companies are actively investing in research and development to address these unmet needs. For example, in January 2025, Celmatix Therapeutics launched a drug development program for a novel JNK inhibitor targeting pain and inflammation in endometriosis, highlighting the industry's shift toward innovation.

Market Restraints

Despite positive growth trends, high treatment costs remain a key restraint. Advanced therapies such as oral GnRH antagonists are significantly more expensive than generic hormonal treatments, limiting accessibility for patients without adequate insurance coverage. High out-of-pocket costs often result in non-adherence or treatment discontinuation.

For instance, the list price of Orilissa was reported at USD 1,046.66 per dose, illustrating the affordability challenges faced by patients and healthcare systems.

Market Opportunities

Rising investments in research and development present lucrative growth opportunities for the market. With current first-line treatments offering limited relief, pharmaceutical companies are focusing on developing novel therapies with improved safety and long-term efficacy.

In January 2025, Gesynta Pharma AB secured USD 28.7 million in Series B funding to advance a Phase II clinical trial for Vipoglanstat, a promising drug candidate for endometriosis. Such investments are expected to accelerate product pipelines and support future market expansion.

Market Trends

A prominent trend in the market is the expansion of awareness campaigns and patient support initiatives. These efforts promote early diagnosis, reduce stigma around menstrual pain, and educate both patients and clinicians.

For example, in March 2025, the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) organized Endometriosis Awareness Month 2025, contributing to increased diagnosis rates and treatment adoption globally.

Market Challenges

Patent infringement and legal disputes pose a critical challenge to market growth. Patent-related litigation can reduce exclusivity periods for innovative drugs, enabling early entry of generics and causing revenue erosion.

In May 2025, AbbVie Inc. filed a patent infringement lawsuit against Hetero Labs Ltd. concerning Orilissa, highlighting the legal risks faced by innovators in this space.

Segmentation Analysis

By drug, the others segment dominates the market due to widespread use of older, cost-effective therapies. Orilissa held an 11.18% market share in 2026, while Myfembree/Ryeqo is expected to grow at a strong CAGR due to recent approvals.

By drug class, GnRH antagonists dominated in 2025 and accounted for 40.17% market share in 2026, driven by faster action and improved safety profiles.

By route of administration, the oral segment dominated with a 65.46% share in 2026, supported by high patient adherence and convenience.

By distribution channel, drug stores and retail pharmacies led the market, holding 59.20% share in 2026.

Regional Outlook

North America led the market with USD 1.19 billion in 2025 and USD 1.28 billion in 2026, driven by strong healthcare infrastructure and rising prevalence.

Europe recorded USD 0.56 billion in 2025, while Asia Pacific reached USD 0.46 billion in 2025, supported by growing awareness in China and India.

Latin America and Middle East & Africa showed moderate growth, with valuations of USD 0.09 billion and USD 0.05 billion respectively in 2025.

Competitive Landscape

The market is semi-consolidated, with key players including AbbVie Inc., Pfizer Inc., Bayer AG, AstraZeneca, and Organon. These companies maintain leadership through strong pipelines, global distribution networks, and continuous R&D investments.

Conclusion

The global endometriosis treatment market is poised for strong growth, expanding from USD 2.39 billion in 2025 to USD 5.03 billion by 2034, driven by rising disease awareness, improved diagnostics, and increasing demand for innovative therapies. While high treatment costs and patent-related challenges may limit adoption, growing R&D investments, non-hormonal drug development, and expanding awareness initiatives are expected to create sustainable growth opportunities. Overall, the market is set to evolve significantly, offering improved treatment outcomes and long-term management solutions for women affected by endometriosis worldwide.

Segmentation By Drug, Drug Class, Route of Administration, Distribution Channel, and Region

By Drug * Orilissa

  • Myfembree/Ryeqo
  • Others

By Drug Class * GnRH Antagonists

  • GnRH Agonists
  • Others

By Route of Administration * Oral

  • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies
  • Online Pharmacies

By Geography * North America (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Epidemiology- Endometriosis, By Key Countries/ Regions
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Orilissa
    • 5.1.2. Myfembree/Ryeqo
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. GnRH Antagonists
    • 5.2.2. GnRH Agonists
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Orilissa
    • 6.1.2. Myfembree/Ryeqo
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. GnRH Antagonists
    • 6.2.2. GnRH Agonists
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. ORILISSA
    • 7.1.2. MYFEMBREE/RYEQO
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. GnRH Antagonists
    • 7.2.2. GnRH Agonists
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Orilissa
    • 8.1.2. Myfembree/Ryeqo
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. GnRH Antagonists
    • 8.2.2. GnRH Agonists
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Southeast Asia
    • 8.5.5. Australia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Orilissa
    • 9.1.2. Myfembree/Ryeqo
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. GnRH Antagonists
    • 9.2.2. GnRH Agonists
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Orilissa
    • 10.1.2. Myfembree/Ryeqo
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. GnRH Antagonists
    • 10.2.2. GnRH Agonists
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. Gesynta Pharma AB
    • 11.2.2. AbbVie Inc.
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Organon group of companies.
    • 11.2.5. Bayer AG
    • 11.2.6. AstraZeneca
    • 11.2.7. Sumitomo Pharma Co., Ltd.

List of Tables

  • Table 1: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 2: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 3: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Endometriosis Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 7: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 11: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 12: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 13: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 17: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 21: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 22: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 27: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 28: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Endometriosis Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Endometriosis Treatment Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
  • Figure 2: Global Endometriosis Treatment Market Value Share (%), By Drug, 2026 & 2034
  • Figure 3: Global Endometriosis Treatment Market Value Share (%), by Drug Class, 2026 & 2034
  • Figure 4: Global Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026 & 2034
  • Figure 5: Global Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026 & 2034
  • Figure 6: Global Endometriosis Treatment Market Value Share (%), by Region, 2026 & 2034
  • Figure 7: North America Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 8: North America Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 9: North America Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 10: North America Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 11: North America Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 12: North America Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 13: North America Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 14: North America Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 15: North America Endometriosis Treatment Market Value (USD billion), by Country, 2026 & 2034
  • Figure 16: North America Endometriosis Treatment Market Value Share (%), by Country, 2026
  • Figure 17: Europe Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 18: Europe Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 19: Europe Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 20: Europe Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 21: Europe Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 22: Europe Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 23: Europe Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 24: Europe Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 25: Europe Endometriosis Treatment Market Value (USD billion), by Country/ Sub-region, 2026 & 2034
  • Figure 26: Europe Endometriosis Treatment Market Value Share (%), by Country/ Sub-region, 2026
  • Figure 27: Asia Pacific Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 28: Asia Pacific Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 29: Asia Pacific Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 30: Asia Pacific Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 31: Asia Pacific Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 32: Asia Pacific Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 33: Asia Pacific Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 34: Asia Pacific Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 35: Asia Pacific Endometriosis Treatment Market Value (USD billion), by Country/ Sub-region, 2026 & 2034
  • Figure 36: Asia Pacific Endometriosis Treatment Market Value Share (%), by Country/ Sub-region, 2026
  • Figure 37: Latin America Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 38: Latin America Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 39: Latin America Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 40: Latin America Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 41: Latin America Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 42: Latin America Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 43: Latin America Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 44: Latin America Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 45: Latin America Endometriosis Treatment Market Value (USD billion), by Country/ Sub-region, 2026 & 2034
  • Figure 46: Latin America Endometriosis Treatment Market Value Share (%), by Country/ Sub-region, 2026
  • Figure 47: Middle East & Africa Endometriosis Treatment Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 48: Middle East & Africa Endometriosis Treatment Market Value Share (%), By Drug, 2026
  • Figure 49: Middle East & Africa Endometriosis Treatment Market Value (USD billion), by Drug Class, 2026 & 2034
  • Figure 50: Middle East & Africa Endometriosis Treatment Market Value Share (%), by Drug Class, 2026
  • Figure 51: Middle East & Africa Endometriosis Treatment Market Value (USD billion), by Route of Administration, 2026 & 2034
  • Figure 52: Middle East & Africa Endometriosis Treatment Market Value Share (%), by Route of Administration, 2026
  • Figure 53: Middle East & Africa Endometriosis Treatment Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 54: Middle East & Africa Endometriosis Treatment Market Value Share (%), by Distribution Channel, 2026
  • Figure 55: Middle East & Africa Endometriosis Treatment Market Value (USD billion), by Country/ Sub-region, 2026 & 2034
  • Figure 56: Middle East & Africa Endometriosis Treatment Market Value Share (%), by Country/ Sub-region, 2026
  • Figure 57: Global Endometriosis Treatment Market Share (%), by Company, 2026